Notably, the results of animal studies and clinical trials suggested that ADT as a monotherapy inhibits the growth of auxotrophic for Arg, i.e., is deficient in argininosuccinate synthetase (ASS1) tumors, but by itself is insufficient for eliminating cancer cells in vivo [7,8,9,10,11,12,13]. This evidence concerns the gene ASS1 and cancer.